PLATCOV
Quantitative evidence of antiviral activity in patients with COVID-19 is required to justify phase 3 clinical trials of putative antivirals, yet there is no optimised or validated approach to rapidly assess potential antiviral therapeutics in COVID-19. Antiviral treatments are most likely to be of benefit when given early in the illness, accelerating viral clearance and thereby reducing the subsequent inflammatory pathology.
Primary objective: To evaluate COVID-19 antiviral efficacy in-vivo of repurposed and newly available drugs including small molecules , and to characterise in-vivo performance over time relative to the no antiviral treatment control.
Type of study: Randomised, open label, group sequential adaptive platform trial
Treatment tested: Drugs with potential SARS-CoV-2 antiviral activity of three general types: Newly available and repurposed potential antiviral drugs ; Monoclonal antibodies; Novel small molecule drugs that have gone through phase 1 testing
Countries: Thailand, Brazil, Pakistan, Laos and yet unconfirmed site(s)
Sample size: Approximately 1500 participants
Study participants: Previously healthy adults, male or female, aged 18 to 50 years at time of consent with early symptomatic COVID-19
Study status: Recruiting.
Principal investigators
- Dr William Schilling, Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
- Professor Sir Nicholas J White, Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
More information
- Study website
- Study ID: NCT05041907
- Trial registry
Last updated: March 2023
Disclaimer
Note that study-related documents posted on the COVID-19 Clinical Research Coalition (COVID-19 CRC) website have been shared by coalition members for information. Some may have been approved by Ethics Review Boards and others may still be in draft form. Documents posted here may have been further amended before being used in the conduct of the respective trials they were designed for. It is recommended that users review these documents carefully and, if they plan to use them, adapt them appropriately for their intended use. The COVID-19 CRC and its members cannot accept any liability for any claim, loss or damages as a result of any reliance placed on, or use of, these documents.